Real-World Efficacy of Atezolizumab in Treating Small Cell Lung Cancer with and without Brain Metastases

Strategic Insights -

Researchers at Tianjin University have conducted a retrospective cohort study to evaluate the effectiveness of atezolizumab combined with etoposide and platinum (EP) chemotherapy compared to EP alone as first-line treatment in patients with extensive-stage small cell lung cancer (ES-SCLC). The study included 95 patients diagnosed with ES-SCLC at Tianjin Chest Hospital between January 2019 and December 2024. The results showed that atezolizumab combined with EP chemotherapy was associated with improved survival outcomes, including overall survival (OS) and progression-free survival (PFS), compared to EP alone. However, the subgroup analysis of patients with brain metastases was inconclusive due to the limited sample size.

Key Takeaways:

  • The study included 95 patients diagnosed with ES-SCLC between January 2019 and December 2024.
  • Atezolizumab combined with EP chemotherapy demonstrated improved OS and PFS compared to EP alone.
  • The subgroup analysis of patients without brain metastases showed significant OS and PFS benefits, while the results in the brain metastasis subgroup were inconclusive due to limited sample size.
  • The study supports the broader applicability of immune-chemotherapy in routine practice and underscores the potential benefit for patients without brain metastases.
  • The combination of atezolizumab with EP chemotherapy was associated with a delayed separation in survival curves and a favorable hazard ratio (0.42, 95% CI: 0.21-0.86).

Statistics:

  • Median OS in the atezolizumab group was 9.7 months, compared to 7.1 months in the EP-only group (hazard ratio = 0.51, 95% CI: 0.30-0.94).
  • Median PFS showed similar values between the groups (5.8 months in the atezolizumab group and 5.7 months in the EP-only group).
  • The subgroup analysis revealed significant OS and PFS benefits among patients without brain metastases.
  • The brain metastasis subgroup had a limited sample size, making the results inconclusive.

Sources:

  • Real-world efficacy of atezolizumab combined with etoposide and platinum chemotherapy in extensive-stage small cell lung cancer: a retrospective cohort study. Journal of Thoracic Disease, 2025;17(7):5210-5222.